Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ostergren

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Journal of Cardiac Failure|September 25, 1999
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme InvestigatorsK Swedberg, M Pfeffer, C Granger, et al.
European Journal of Heart Failure|June 12, 2003
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programmeJ McMurray, J Ostergren, M Pfeffer, et al.
International Angiology : a Journal of the International Union of Angiology|March 24, 2011
The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemiaJ J F Belch, S Ray, M Rajput-Ray, et al.
Journal of Hypertension|June 14, 2001
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigatorsP S Sever, B Dahlöf, N R Poulter, et al.
Heart (British Cardiac Society)|September 6, 2006
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeN M Hawkins, D Wang, J J V McMurray, et al.
International Journal of Clinical Practice|October 12, 2001
What is the relevance of the HOPE study in general practice?J Kennedy, C E Mogensen, S G Ball, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Journal of Cardiac Failure|September 25, 1999
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme InvestigatorsK Swedberg, M Pfeffer, C Granger, et al.
European Journal of Heart Failure|June 12, 2003
Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programmeJ McMurray, J Ostergren, M Pfeffer, et al.
International Angiology : a Journal of the International Union of Angiology|March 24, 2011
The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemiaJ J F Belch, S Ray, M Rajput-Ray, et al.
Journal of Hypertension|June 14, 2001
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigatorsP S Sever, B Dahlöf, N R Poulter, et al.
Heart (British Cardiac Society)|September 6, 2006
Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programmeN M Hawkins, D Wang, J J V McMurray, et al.
International Journal of Clinical Practice|October 12, 2001
What is the relevance of the HOPE study in general practice?J Kennedy, C E Mogensen, S G Ball, et al.
Pageof 6